NVAX NOVAVAX INC US FDA Inspections 8-K Filing 2024 - FDA Clinical Hold Novavax announced that the FDA has placed a clinical hold on its COVID-19-Influenza Combination vaccine due to a serious adverse event reported in a trial participant, which may delay the Phase 3 trial.Get access to all SEC 8-K filings of the NOVAVAX INC